Show simple item record

dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorPapakotoulas, Pavlos I
dc.contributor.authorDanson, Sarah
dc.contributor.authorThatcher, Nick
dc.date.accessioned2009-08-10T10:48:03Z
dc.date.available2009-08-10T10:48:03Z
dc.date.issued2005-06
dc.identifier.citationPerspectives on novel therapies for bronchial carcinoma. 2005, 6 (7):1157-67 Expert Opin Pharmacotheren
dc.identifier.issn1744-7666
dc.identifier.pmid15957969
dc.identifier.doi10.1517/14656566.6.7.1157
dc.identifier.urihttp://hdl.handle.net/10541/76783
dc.description.abstractImprovements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarcinoma, Bronchogenic
dc.subject.meshCarcinoma, Small Cell
dc.subject.meshCyclooxygenase 2 Inhibitors
dc.subject.meshDrug Administration Schedule
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshPatient Selection
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyrazoles
dc.subject.meshQuinazolines
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshReceptor, Epidermal Growth Factor
dc.subject.meshSulfonamides
dc.subject.meshVascular Endothelial Growth Factor A
dc.titlePerspectives on novel therapies for bronchial carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uken
dc.identifier.journalExpert Opinion on Pharmacotherapyen
html.description.abstractImprovements in conventional cytotoxic treatment have probably reached a plateau for the treatment of lung cancer; therefore, new treatment strategies that are based on a better understanding of tumour biology are required. Some progress has been made for non-small cell lung cancer, in which erlotinib (Tarceva, OSI-774; Genentech), an epidermal growth factor receptor antagonist, has demonstrated a significant clinical benefit in a Phase III randomised trial, and has been licensed for second- or third-line treatment. Other therapies under investigation include angiogenesis inhibitors, COX-2 inhibitors, retinoids, farnesyl transferase inhibitors, Bcl-2 inhibitors and c-Kit antagonists. In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed.


This item appears in the following Collection(s)

Show simple item record